ClinicalTrials.gg
RecruitingNCT05556018CardioInsight3Updated Feb 16, 2024

CardioInsight 3 - LBBB

An interventional study of Electrical Activation Mapping Guided Cardiac resynchronization therapy in Heart Failure, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-16.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 2 months after the study started (first participant enrolled Jul 2019, registered Sep 2022).
  • Started Jul 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Heart Failure by Chinese University of Hong Kong — 7 open to participants now, 7 under way, 1 of them phase 3. Heart Failure · Chinese University of Hong Kong.

Started
2019
the only one that year
No phase
7 of 15
2 open now
Registered
9th of 15
by date

Among the 15 studies in Heart Failure by Chinese University of Hong Kong, this one is the only one that started in 2019, is one of 7 with no phase, and was the 9th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

7 of the 15 studies in Heart Failure by Chinese University of Hong Kong are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Heart Failure by Chinese University of Hong Kong, or all of them as a file.
02

Study summary

Background Cardiac Resynchronization Therapy (CRT) is proven to improve survival and heart function of patient with certain electrical conduction abnormality and heart failure. However, in patient with certain electrical conduction abnormality, being nonresponder is observed in up to 40% in patient receiving CRT. Conventionally the surgical approach of CRT is to implant one pacing lead in the right heart and one in the left heart to resynchronize the contraction and the pacing lead in the left heart is usually placed in the posterior or lateral portion of the left heart. However, this single approach may not be optimal, especially for those patients with conduction abnormality known to have no response to CRT. Purpose of the clinical investigation The purpose of the Activation Pattern and Acute Hemodynamics of His and Left Bundle Pacing is to study the acute effect on the heart function and conduction abnormality of His and left bundle pacing in conventional CRT candidate. During CRT implantation, Hisbundle lead and Left bundle pacing lead will be placed and the acute effect on heart function will be studied by a wire placed in the left ventricle of the heart and the activation pattern will be studied by a noninvasive global mapping system. The pacing approach that optimally corrects conduction abnormality and improvement on the heart function acutely will be determined

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (aged 18 or above) of both sexes
  • Candidate for CRT therapy according to international guidelines.7
  • by the patient
  • Already received stable dose of guideline directed medical therapy for at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • Participating in another study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Tailor-made CRT delivery

    Cardiac resynchronization therapy given according to Electrical Activation Mapping result

    Device: Electrical Activation Mapping Guided Cardiac resynchronization therapy

Interventions

  • DeviceElectrical Activation Mapping Guided Cardiac resynchronization therapy

    To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation

06

What researchers measure

Primary outcomes

  1. Improvement in myocardiac activation

    Correction of activation abnormality as evaluated by global noninvasive mapping system (ECGi) seen as an increase in acute dp/dt \> 5% from baseline with left bundle pacing comparing to biventricular pacing.

    Time frame: 6 months

Secondary outcomes

  1. Procedure duration

    Procedure duration of the optimal CRT delivery method as determined by the best improvement in electrical desynchrony indices.

    Time frame: during procedure

  2. Implantation success rate

    Implantation success rate of the optimal CRT delivery method as determined by the best improvement in electrical desynchrony indices.

    Time frame: during procedure

  3. Cine images and chest X ray

    Cine images (PA, LAO 300, RAO 300) and Chest X ray (PA view) obtained during course of study for assessment of disease

    Time frame: 6 months

  4. Echocardiogram parameters: strain imaging

    Echocardiogram parameters: strain imaging at baseline, 3 months and 6 months

    Time frame: 6 months

  5. Echocardiogram parameters: left ventricular systolic and diastolic volume

    Echocardiogram parameters: left ventricular systolic and diastolic volume at baseline, 3 months and 6 months

    Time frame: 6 months

  6. Echocardiogram parameters: left ventricular ejection fraction

    Echocardiogram parameters: left ventricular ejection fraction at baseline, 3 months and 6 months

    Time frame: 6 months

  7. Echocardiogram parameters: degree of mitral regurgitation

    Echocardiogram parameters at baseline, 3 months and 6 months

    Time frame: 6 months

  8. Change in New York Heart Association class

    Comparison of NYHA class at baseline, 3 months and 6 months to assess changes in quality of life of subject.

    Time frame: 6 months

  9. Device parameter: defibrillation threshold

    Electrical parameters including defibrillation threshold at implant and 6 months follow-up.

    Time frame: 6 months

  10. post-operative complication rate

    Peri-operative and 6 months follow-up complications rate: 1. Thromboembolic event 2. Dislodgement and migration of pacing leads 3. Phrenic nerve stimulation 4. Others

    Time frame: 6 months

  11. Device parameter: defibrillation sensitivity

    Electrical parameters including defibrillation sensitivity at implant and 6 months follow-up.

    Time frame: 6 months

  12. Device parameter: lead impedance

    Electrical parameters including lead impedance of pacing leads at addition of new lead and 6 months follow-up.

    Time frame: 6 months

  13. Change in 6 minute hall walk test result

    Comparison of 6 minute hall walk test result at baseline, 3 months and 6 months to assess changes in quality of life of subject.

    Time frame: 6 months

  14. Change in HF Patient Global Assessment Questionnaire outcome

    Comparison of HF Patient Global Assessment Questionnaire outcome at baseline, 3 months and 6 months to assess changes in quality of life of subject.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Dec 2023, 53 months.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 53 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2022
First posted
Sep 27, 2022
StartActual
Jul 5, 2019
Primary completionActual
Dec 31, 2023
CompletionEst.
Mar 31, 2024
Last update
Feb 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05556018
Responsible party
Professor Bryan Ping Yen YAN (Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Sep 27, 2022
Start date
Jul 5, 2019
Primary completion
Dec 31, 2023
Completion
Mar 31, 2024 (estimated)
Last update
Feb 16, 2024

Study contacts

Daniel Xu
Contact
danielxu@cuhk.edu.hk
35051518
Bryan Yan
principal investigator · Chinese University of Hong Kong

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion